Related Articles
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors
Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer
Multicenter phase II study of infusional 5‑fluorouracil (5‑FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first‑line treatment in patients with metastatic colorectal cancer (CELINE trial)
Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer
Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy